Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aeglea Biothera (NQ: AGLE )

7.700 USD +0.090 (+1.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 21, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 184,304
Open 7.590
Bid (Size) 7.700 (3)
Ask (Size) 7.720 (4)
Prev. Close 7.610
Today's Range 7.510 - 7.850
52wk Range 5.820 - 9.900
Shares Outstanding 49,064,558
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Aeglea BioTherapeutics to Participate in Multiple Conferences in September 2021
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today... 
From PR Newswire
Aeglea BioTherapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights
Initiated Dosing in Phase 1/2 Clinical Trial of AGLE-177 in Homocystinuria 
From PR Newswire

Performance

YTD
-10.05%
-10.05%
1 Month
+7.84%
+7.84%
3 Month
+20.88%
+20.88%
6 Month
-10.15%
-10.15%
1 Year
+6.80%
+6.80%

More News

Read More
Aeglea BioTherapeutics Appoints Jim Kastenmayer as General Counsel
From PR Newswire
Aeglea BioTherapeutics Announces Publication of 20 Week Data from Phase 1/2 and Open-Label Extension Studies of Pegzilarginase for the Treatment of Arginase 1 Deficiency in the Journal of Inherited Me
From PR Newswire
Aeglea BioTherapeutics Appoints Jonathan D. Alspaugh as Chief Financial Officer
From PR Newswire
Aeglea BioTherapeutics Doses First Patient in a Phase 1/2 Clinical Trial of AGLE-177, a Potential First-in-Class Treatment for Homocystinuria
From PR Newswire
Aeglea BioTherapeutics Appoints Marcio Souza to Board of Directors
From PR Newswire
Aeglea BioTherapeutics Reports First Quarter 2021 Financial Results and Corporate Highlights
From PR Newswire
Top Buys by Top Brass: Chief Financial Officer Alspaugh's $262.7K Bet on AGLE
Tags Stocks
From Market News Video
Aeglea BioTherapeutics Launches THINK ARGININE™, a Disease Education Initiative to Improve Awareness and Diagnosis of Arginase 1 Deficiency
From PR Newswire
Asher Bio Appoints Leading Experts in Immunology, Oncology and Protein Therapeutics to its Scientific Advisory Board
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.